Testing tirzepatide to study markers of early-onset colorectal tumor risk
Tests tirzepatide in adults aged 18 to 50 to study colorectal cancer risk markers.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 20 people, planned
- Started
- 24 Feb 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Tirzepatide
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-50 who had colon or rectal adenomas removed at a recent colonoscopy and are overweight. It tests tirzepatide and blood, urine, tissue and gut bacteria markers linked to colorectal cancer risk.
- Age
- 18 to 50 years
- Sex
- All sexes can join.
- Disease stage
- At the last colonoscopy, at least 2 colon or rectal adenomas were removed (sessile serrated adenomas count, hyperplastic polyps do not), or a single adenoma of 6mm or larger.
- Earlier treatment
- Must never have taken incretin mimetic therapies. The colonoscopy with adenoma removal must have been within the prior 9 months.
Main reasons for not taking part
- History of diabetes mellitus
- History of medullary thyroid cancer or MEN 2 syndrome
- History of cancer (except non-melanoma skin) within the last three years
- Hereditary cancer syndromes such as Lynch syndrome or familial adenomatous polyposis
- Pregnant, or a history of bowel surgery or inflammatory bowel disease
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18-50 years Because no dosing or adverse event data are currently available on the use of tirzepatide in participants <18 years of age, children are excluded from this study. Because we are specifically studying the prevention of EOCRC, which is defined as CRC occurring prior to age 50, the study population will only enroll participants under the age of 50 at baseline
- BMI between 27 and 40 kg/m2
- Underwent a screening or surveillance colonoscopy within the prior 9 months
- Removal of multiple (at least 2) colon or rectal adenomas (including sessile serrated adenomas but excluding hyperplastic polyps) or a single adenoma ≥6mm in size during the last colonoscopy
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Participants who have ever taken incretin mimetic therapies
- Participants with incomplete or partial polypectomy during prior colonoscopy
- Participants with a history of medullary thyroid cancer or MEN 2 syndrome
- Participants with a history of cancer (excluding non-melanoma skin) within the last three years
- Participants with a history of diabetes mellitus
- Participants with a history of bowel surgery
- Participants with hereditary cancer syndromes, including HNPCC/Lynch syndrome or familial adenomatous polyposis
- Participants with a history of inflammatory bowel disease, Crohn's, or colitis
- Participants at high risk of pancreatitis or otherwise contraindicated for use of tirzepatide according to clinical labeling
- Participants who are pregnant. Participants who may become pregnant or partners of those who may become pregnant while on study will receive contraception counseling. Participants or partners of those who become pregnant while participating on the study should immediately inform their doctor
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in United States
- Massachusetts General Hospital Cancer CenterBoston, United StatesContact: Andrew T. Chan, MD, MPHTaking people
About the trial
What the trial wants to find out
This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial approach for a future larger study.
The group in the trial
- TirzepatideTreatment being tested
Participants will be instructed to inject tirzepatide 1 time per week for up to 24 weeks. The dose will start with a 2.5mg injection per week for the first 4 weeks. Dose will increase 2.5mg/injection every 4 weeks until 15mg/injection (or maximum tolerable dose) per week is reached.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
- Plain-language title
- Testing tirzepatide to study markers of early-onset colorectal tumor riskGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07095517, who can take part
- Record updated
- 27 February 2026